Who we are

LIFEFACTORS WAS BORN TO ENSURE ACCESS TO ESSENTIAL MEDICATIONS FOR THE TREATMENT OF RARE AND HIGH COST DISEASES

Since 2017, after acquiring the Dual-Phase Aqueous Separation System (SDFA for its acronym in Spanish) patented technology, we have built a series of solutions to support governments and healthcare systems in the implementation of this technology in their territories granting them the autonomy to produce and distribute blood derived products.

2017

Beginning of the technology transfer

2019

Construction of the Scale A Manufacturing Plant. Scaling up processes. GMP request. First contracts.

2021

Latam regulatory processes.

2023

International expansion.

2018

Foundation of LifeFactors.

2020

Design and feasibility of the Scale I Manufacturing Plant.

2022

GMP process. Scale A Manufacturing Plant. Beginning of the construction of the Scale I Manufacturing Plant.

2024

Operations of the Scale I Manufacturing Plant. Commercial product launch.

2017

Beginning of the technology transfer

2018

Foundation of LifeFactors.

2019

Construction of the Scale A Manufacturing Plant. Scaling up processes. GMP request. First contracts.

2020

Design and feasibility of the Scale I Manufacturing Plant.

2021

Latam regulatory processes.

2022

GMP process. Scale A Manufacturing Plant. Beginning of the construction of the Scale I Manufacturing Plant.

2023

International expansion.

2024

Operations of the Scale I Manufacturing Plant. Commercial product launch.

WITH THESE ATTRIBUTES WE CAN HELP THE REGION BY HARNESSING THE HUMAN PLASMA CONTRIBUTING TO EACH ONE OF ITS HEALTHCARE SYSTEMS BY:

IMPROVING THE NATIONAL BLOOD SYSTEM

IMPLEMENTING A DISRUPTIVE AND INNOVATIVE TECHNOLOGY THAT SURPASSES THE CURRENT PRODUCTIVITY LEVELS

ADVANCING IN THE BLOOD DERIVED PRODUCT SELF-SUFICIENCY

Global Solutions

OBJECTIVE:
As our greatest commitment
is to life, we are committed
to innovating with health biosolutions that have a global reach.

Objetctive

We contribute
to the accelerated
GROWTH
Of the demand

With an
EXCHANGE VALUE
model

Technology that
PROMOTES
self-sufficiency

We enable and
FACILATE
the plasma process

We implement mutual
IMPROVEMENT
actions

We REDUCE
shortage and high
production costs

Innovation in the ecosystem

A modular pharmaceutical industrialization model to produce blood derived products, under the main international quality standards (incremental capacities of 50 - 300 thousand liters of plasma each year).

A system for converting discarded recovered plasma, today incinerated, into pharmaceutical raw material. It is estimated that LATAM has more than 1.7 million liters of unused plasma in the blood transfusion system.

Insertion in modern models of drug marketing and comprehensive patient care in pathologies such as: immunology, haemato-oncology, hemophilia, neurological, among others. All of them of high cost and more complex for the health systems of the countries.

Internal knowledge networks with an ecosystem specialized in biopharmaceutical policies and regulations, clinical research, bioengineering and the development of biological medicinal products.

Better
yield

MORE AVAILABILITY of blood
derived products per LITRE OF PROCESSED PLASMA.

INCREASE in EFFICIENCY
in production costs.

QUALITY, SAFETY AND EFFICACY
of biological medicinal products, according to the European Pharmacopeia standards

COMPLIANCE with INTERNATIONAL QUALITY STANDARDS, based on Good Pharmaceutical Manufacturing Practices

Shared value

Bio-
solutions

LIFEFACTORS SUPPORTS COUNTRIES WITH TECHNOLOGIES
THAT ALLOW THEM TO IMPROVE THE QUALITY AND QUANTITY
CONDITIONS OF THEIR PLASMA TO OBTAIN AN INDUSTRIAL USE THUS
PROVIDING THE NECESSARY BIOLOGICAL MEDICINAL PRODUCTS
FOR THEIR PATIENTS.

Therapeutic approach

Once acknowledging the benefits of blood derived products, their demand has increased in recent years due to their contribution to more than 200 clinical conditions.

This is why in LifeFactors we focus on efficient biosolutions and innovative production technology to positively contribute to humanity.

Blood derived
products